Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Unity Biotechnology Q2 EPS $(0.19) Up From $(0.32) YoY

Unity Biotechnology Q2 EPS $(0.19) Up From $(0.32) YoY

Unity Biotechnology (NASDAQ:UBX) reported quarterly losses of $(0.19) per share. This is a 40.63 percent increase over losses of $(0.32) per share from the same period last year.

byBill Haddad

August 12, 2022

1 minute read

Unity Biotechnology (NASDAQ:UBX) reported quarterly losses of $(0.19) per share. This is a 40.63 percent increase over losses of $(0.32) per share from the same period last year.

Skillz Sees FY22 Revenue $275M Vs $399.13M Est

By Benzinga Newsdesk

August 3, 5:21 PM

We are lowering our full-year 2022 revenue guidance to $275 million. Our revised guidance is based on engagement marketing as a percentage of revenue of approximately 42% and implies

SKLZ

VCI Global Secures Its First IPO Consultancy Deal In 2024 With A Singapore-Based Fin-MedTech Medical Group; IPO On Nasdaq Is Expected To Be Completed In 2024/2025

By Benzinga Newsdesk

January 23, 9:22 AM

VCI Global Limited (NASDAQ:VCIG) ("VCI Global", or the "Company") has been engaged by a Singapore-based Fin-MedTech Medical Group (the "Medical Group") as its initial public offering ("IPO") consultant for its intended

VCIG